Lowenstein Sandler represented Matinas BioPharma Holdings, Inc. (MTNB-OTCQB) in connection with a $10 million private placement, which closed on April 10, 2015. Matinas sold to accredited investors an aggregate of 20,000,000 units at a price of $0.50 per unit, with each unit consisting of one share of the Company's common stock and a five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share. SternAegis Ventures, through Aegis Capital Corp., acted as the exclusive Placement Agent for the offering. The Lowenstein deal team was led by Steven M. Skolnick, Michael J. Lerner, Meredith Prithviraj, Irina Ishak and Robert Bee, Jr.
Relevant Insights
-
PROFESSIONALS | Lawyers
Access the profiles of the more than 350 Lowenstein Sandler lawyers who provide critical legal counsel to clients in virtually every sector of the global economy...
-
NEWS & INSIGHTS | Firm News
Discover the latest updates and developments about Lowenstein Sandler...
-
NEWS & INSIGHTS | Publications
Access our insightful thought leadership, including articles, client alerts, and blog posts...